Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: data from the open-label, long-term extension study, OCTAVE open.

"CONFLICT OF INTERESTS RP has received advisory and/or consultation fees from AI4GI, AbbVie, Amgen, Arena Pharmaceuticals, Atlantic Healthcare, BioBalance, Boehringer Ingelheim, Bristol‐Myers Squibb, Celgene, Coronado Biosciences, Cosmo Technologies, Eagle, Eisai Medical Research, Elan, Eli Lilly, EnGene, Ferring Pharmaceuticals, Genentech, Gilead Sciences, Given Imaging, GlaxoSmithKline, Innomar, Janssen, Lycera, Meda, Merck & Co., Merck Research Laboratories, Novo Nordisk, PDL Biopharma, Pfizer Inc, Prometheus Laboratories, Protagonist, Receptos, Robarts Clinical Trials, Sandoz, Sanofi Genzyme, Satisfai Health, Shire Pharmaceuticals, Sigmoid Pharma, Specialty Rx, Sublimity, Takeda and TherAdvance. MTA has served as a trainer/lecturer for Cornerstones Health, Inc, Focus Medical Communications, Imedex, Janssen and Prime CME; and has served as a consultant or advisor to AbbVie, Bellatrix Pharmaceuticals, Boehringer Ingelheim, Bristol‐Myers Squibb, Eli Lilly, Gilead Sciences, Prometheus Biosciences, Takeda and UCB Biopharma SRL. IL is an employee of IQVIA, which was a paid contractor to Pfizer in connection with the development of this manuscript and in providing statistical support. RM, NL, LS and JCW are all employees and stockholders of Pfizer Inc. BES has received consulting fees from 4D Pharma, AbbVie, Allergan, Amgen, Arena Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Boston Pharmaceuticals, Capella Biosciences, Celgene, Celltrion Healthcare, Eli Lilly, EnGene, Ferring Pharmaceuticals, Genentech, Gilead Sciences, Hoffmann‐La Roche, Immunic, Ironwood Pharmaceuticals, Janssen, Lyndra, MedImmune, Morphic Therapeutic, Oppilan Pharma, OSE Immunotherapeutics, Otsuka, Palatin Technologies, Pfizer Inc, Progenity, Prometheus Laboratories, Redhill Biopharma, Rheos Medicines, Seres Therapeutics, Shire Pharmaceuticals, Synergy Pharmaceuticals, Takeda, Target RWE, Theravance Biopharma R&D, TiGenix and Vivelix Pharmaceuticals; has received honoraria for speaking in CME programmes from Eli Lilly, Genetech, Gilead Sciences, Janssen, Pfizer Inc and Takeda; and has received research funding from Celgene, Janssen, Pfizer Inc, Takeda and Theravance Biopharma R&D. MC has served as a speaker, consultant and advisory member for, or received research funding from, AbbVie, Celltrion, Chiesi, Faes Farma, Falk Pharma, Ferring Pharmaceuticals, Gebro Pharma, Janssen, MSD, Otsuka Pharmaceuticals, Pfizer Inc, Roche, Shire Pharmaceuticals, Takeda and Tillotts Pharma."

"Funding information This study was sponsored by Pfizer. Medical writing support, under the guidance of the authors, was provided by Helen Findlow, PhD, CMC Connect, McCann Health Medical Communications and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines ( Ann Intern Med . 2015;163:461–464). Irina Lazariciu is an employee of IQVIA, which was a paid contractor to Pfizer in connection with the development of this manuscript and in providing statistical support."

"This study was conducted in compliance with the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice Guidelines, and was approved by the Institutional Review Boards and/or Independent Ethics Committees at each investigational centre, or a central Institutional Review Board. All patients provided written informed consent. All authors had access to the study data and reviewed and approved the final manuscript. OCTAVE Open is registered at ClinicalTrials.gov: NCT01470612."